Efficacy of Elexacaftor–Tezacaftor–Ivacaftor in the Treatment of Cystic Fibrosis and CFTRN1303K in the US
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
Lancet Respir Med 2024 Aug 26;[EPub Ahead of Print], GM Solomon, RW Linnemann, R Rich, A Streby, B Buehler, E Hunter, K Vijaykumar, WR Hunt, JJ Brewington, A Rab, SP Bai, AL Westbrook, C McNicholas-Bevensee, J Hong, C Manfredi, C Barilla, S Suzuki, BR Davis, EJ SorscherFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.